HMGB1 overexpression as a prognostic factor for survival in cancer: A meta-analysis and systematic review

Oncotarget

Volumn 7, Issue 31, 2016, Pages 50417-50427

  Wu, Tengyun ^a   Zhang, Wei ^b   Yang, Geliang ^b   Li, Huijun ^c   Chen, Qi ^d   Song, Ruixiang ^b   Zhao, Lin ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c Department of Internal Medicine Wright Center   (United States)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; High mobility group box 1; Meta analysis; Prognosis factor; Survival

Indexed keywords

BIOLOGICAL MARKER; HIGH MOBILITY GROUP B1 PROTEIN; HMGB1 PROTEIN, HUMAN; TUMOR MARKER;

BLADDER CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CANCER; GEOGRAPHIC DISTRIBUTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PANCREAS CANCER; PLEURA MESOTHELIOMA; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; STOMACH CANCER; UTERINE CERVIX CARCINOMA; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GEOGRAPHY; META ANALYSIS; METABOLISM; MORTALITY; NEOPLASM; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GEOGRAPHY; HMGB1 PROTEIN; HUMANS; NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 84981341597     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10413     Document Type: Review

References (57)

1. All Cancers (excluding non-melanoma skin cancer) Estimated Incidence, Mortality and Prevalence Worldwide in 2012. World Health Organization. Website: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed September 27, 2015.
2. Zhao H, Guo L, Zhao J, Weng H and Zhao B. CXCR4 over-expression and survival in cancer: a system review and meta-analysis. Oncotarget. 2015; 6:5022-5040. doi: 10.18632/oncotarget.3217.
3. Esposito A, Criscitiello C, Locatelli M, Milano M and Curigliano G. Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. Pharmacology & therapeutics. 2015.
4. Goodwin GH and Johns EW. Isolation and characterisation of two calf-thymus chromatin non-histone proteins with high contents of acidic and basic amino acids. European journal of biochemistry/FEBS. 1973; 40:215-219.
5. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999; 285:248-251.
6. Kang R, Chen R, Zhang Q, Hou W, Wu S, Cao L, Huang J, Yu Y, Fan XG, Yan Z, Sun X, Wang H, Wang Q, Tsung A, Billiar TR, Zeh HJ, 3rd, et al. HMGB1 in health and disease. Molecular aspects of medicine. 2014; 40:1-116.
7. Thanos D and Maniatis T. The high mobility group protein HMG I(Y) is required for NF-kappa B-dependent virus induction of the human IFN-beta gene. Cell. 1992; 71:777-789.
8. Baldassarre G, Battista S, Belletti B, Thakur S, Pentimalli F, Trapasso F, Fedele M, Pierantoni G, Croce CM and Fusco A. Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Molecular and cellular biology. 2003; 23:2225-2238.
9. Fashena SJ, Reeves R and Ruddle NH. A poly(dA-dT) upstream activating sequence binds high-mobility group I protein and contributes to lymphotoxin (tumor necrosis factor-beta) gene regulation. Molecular and cellular biology. 1992; 12:894-903.
10. Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A and Lotze MT. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res. 2007; 13:2836-2848.
11. Lotze MT and DeMarco RA. Dealing with death: HMGB1 as a novel target for cancer therapy. Curr Opin Investig Drugs. 2003; 4:1405-1409.
12. Tang D, Kang R, Zeh HJ, 3rd and Lotze MT. High-mobility group box 1 and cancer. Biochimica et biophysica acta. 2010; 1799:131-140.
13. Kang R, Zhang Q, Zeh HJ, 3rd, Lotze MT and Tang D. HMGB1 in cancer: good, bad, or both? Clin Cancer Res. 2013; 19:4046-4057.
14. Akaike H, Kono K, Sugai H, Takahashi A, Mimura K, Kawaguchi Y and Fujii H. Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer. Anticancer research. 2007; 27:449-457.
15. He W, Tang B, Yang D, Li Y, Song W, Cheang T, Chen X, Chen L, Zhan W, Li W and He Y. Double-positive expression of high-mobility group box 1 and vascular endothelial growth factor C indicates a poorer prognosis in gastric cancer patients. World journal of surgical oncology. 2013; 11:161.
16. Zhang J, Zhang R, Lu WW, Zhu JS, Xia LQ, Lu YM and Chen NW. Clinical significance of hmgb1 expression in human gastric cancer. International journal of immunopathology and pharmacology. 2014; 27:543-551.
17. Yao X, Zhao G, Yang H, Hong X, Bie L and Liu G. Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. Journal of cancer research and clinical oncology. 2010; 136:677-684.
18. Peng RQ, Wu XJ, Ding Y, Li CY, Yu XJ, Zhang X, Pan ZZ, Wan DS, Zheng LM, Zeng YX and Zhang XS. Co-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO+ T cells and prognosis in patients with stage IIIB colon cancer. BMC cancer. 2010; 10:496.
19. Soldevilla B, Diaz R, Silva J, Campos-Martin Y, Munoz C, Garcia V, Garcia JM, Pena C, Herrera M, Rodriguez M, Gomez I, Mohamed N, Marques MM, Bonilla F and Dominguez G. Prognostic impact of DeltaTAp73 isoform levels and their target genes in colon cancer patients. Clin Cancer Res. 2011; 17:6029-6039.
20. Ueda M, Takahashi Y, Shinden Y, Sakimura S, Hirata H, Uchi R, Takano Y, Kurashige J, Iguchi T, Eguchi H, Sugimachi K, Yamamoto H, Doki Y, Mori M and Mimori K. Prognostic significance of high mobility group box 1 (HMGB1) expression in patients with colorectal cancer. Anticancer research. 2014; 34:5357-5362.
21. Liu F, Zhang Y, Peng Z, Gao H, Xu L and Chen M. High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. Journal of translational medicine. 2012; 10:135.
22. Xiao J, Ding Y, Huang J, Li Q, Liu Y, Ni W, Zhang Y, Zhu Y, Chen L and Chen B. The association of HMGB1 gene with the prognosis of HCC. PloS one. 2014; 9:e89097.
23. Chung HW, Lim JB, Jang S, Lee KJ, Park KH and Song SY. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. Cancer science. 2012; 103:1714-1721.
24. Wittwer C, Boeck S, Heinemann V, Haas M, Stieber P, Nagel D and Holdenrieder S. Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy. International journal of cancer. 2013; 133:2619-2630.
25. Wu D, Ding Y, Wang S, Zhang Q and Liu L. Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. The Journal of pathology. 2008; 216:167-175.
26. Liu Y, Xie C, Zhang X, Huang D, Zhou X, Tan P, Qi L, Hu G, Tian Y and Qiu Y. Elevated expression of HMGB1 in squamous-cell carcinoma of the head and neck and its clinical significance. Eur J Cancer. 2010; 46:3007-3015.
27. Chuangui C, Peng T and Zhentao Y. The expression of high mobility group box 1 is associated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma. Pathology oncology research: POR. 2012; 18:1021-1027.
28. Tabata C, Shibata E, Tabata R, Kanemura S, Mikami K, Nogi Y, Masachika E, Nishizaki T and Nakano T. Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma. BMC cancer. 2013; 13:205.
29. Yang GL, Zhang LH, Bo JJ, Huo XJ, Chen HG, Cao M, Liu DM and Huang YR. Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. Journal of surgical oncology. 2012; 106:57-61.
30. Li T, Gui Y, Yuan T, Liao G, Bian C, Jiang Q, Huang S, Liu B and Wu D. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy. BJU international. 2012; 110:E1125-1130.
31. Sheng X, Du X, Zhang X, Li D, Lu C, Li Q, Ma Z, Song Q and Wang C. Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels. Croatian medical journal. 2009; 50:455-464.
32. Johann DJ, Jr., McGuigan MD, Patel AR, Tomov S, Ross S, Conrads TP, Veenstra TD, Fishman DA, Whiteley GR, Petricoin EF, 3rd and Liotta LA. Clinical proteomics and biomarker discovery. Annals of the New York Academy of Sciences. 2004; 1022:295-305.
33. Liu Y, Prasad R and Wilson SH. HMGB1: roles in base excision repair and related function. Biochimica et biophysica acta. 2010; 1799:119-130.
34. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
35. Zhang L, Han J, Wu H, Liang X, Zhang J, Li J, Xie L, Xie Y, Sheng X and Yu J. The association of HMGB1 expression with clinicopathological significance and prognosis in hepatocellular carcinoma: a meta-analysis and literature review. PloS one. 2014; 9:e110626.
36. Lotze MT and Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nature reviews Immunology. 2005; 5:331-342.
37. Wu TY, Liu L, Zhang W, Zhang Y, Liu YZ, Shen XL, Gong H, Yang YY, Bi XY, Jiang CL and Wang YX. High-mobility group box-1 was released actively and involved in LPS induced depressive-like behavior. Journal of psychiatric research. 2015; 64:99-106.
38. Klune JR, Dhupar R, Cardinal J, Billiar TR and Tsung A. HMGB1: endogenous danger signaling. Mol Med. 2008; 14:476-484.
39. Passalacqua M, Zicca A, Sparatore B, Patrone M, Melloni E and Pontremoli S. Secretion and binding of HMG1 protein to the external surface of the membrane are required for murine erythroleukemia cell differentiation. FEBS letters. 1997; 400:275-279.
40. Wahamaa H, Vallerskog T, Qin S, Lunderius C, LaRosa G, Andersson U and Harris HE. HMGB1-secreting capacity of multiple cell lineages revealed by a novel HMGB1 ELISPOT assay. Journal of leukocyte biology. 2007; 81:129-136.
41. Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, Zitvogel L and Kroemer G. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis. 2009; 14:364-375.
42. Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, Watkins S, Winikoff S, Brown CK, Bartlett DL and Zeh HJ, 3rd. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother. 2007; 30:596-606.
43. Schiraldi M, Raucci A, Munoz LM, Livoti E, Celona B, Venereau E, Apuzzo T, De Marchis F, Pedotti M, Bachi A, Thelen M, Varani L, Mellado M, Proudfoot A, Bianchi ME and Uguccioni M. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. The Journal of experimental medicine. 2012; 209:551-563.
44. van Beijnum JR, Dings RP, van der Linden E, Zwaans BM, Ramaekers FC, Mayo KH and Griffioen AW. Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood. 2006; 108:2339-2348.
45. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 2000; 405:354-360.
46. Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ and Rauvala H. Receptor for advanced glycation end productsbinding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer research. 2002; 62:4805-4811.
47. van Beijnum JR, Nowak-Sliwinska P, van den Boezem E, Hautvast P, Buurman WA and Griffioen AW. Tumor angiogenesis is enforced by autocrine regulation of highmobility group box 1. Oncogene. 2013; 32:363-374.
48. He J, Zhang P, Li Q, Zhou D and Liu P. Expression of high mobility group box 1 protein predicts a poorer prognosis for patients with osteosarcoma. Oncology letters. 2016; 11:293-298.
49. Paek J, Lee M, Nam EJ, Kim SW and Kim YT. Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer. Archives of gynecology and obstetrics. 2016; 293:645-650.
50. Liu PL, Tsai JR, Hwang JJ, Chou SH, Cheng YJ, Lin FY, Chen YL, Hung CY, Chen WC, Chen YH and Chong IW. High-mobility group box 1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness. American journal of respiratory cell and molecular biology. 2010; 43:530-538.
51. Takeuchi A, Yamamoto Y, Tsuneyama K, Cheng C, Yonekura H, Watanabe T, Shimizu K, Tomita K, Yamamoto H and Tsuchiya H. Endogenous secretory receptor for advanced glycation endproducts as a novel prognostic marker in chondrosarcoma. Cancer. 2007; 109:2532-2540.
52. Wei Y and Niu B. Role of MALAT1 as a Prognostic Factor for Survival in Various Cancers: A Systematic Review of the Literature with Meta-Analysis. Disease markers. 2015; 2015:164635.
53. Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I, Pass HI, Gaudino G, Carbone M and Yang H. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer research. 2012; 72:3290-3301.
54. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J and Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS medicine. 2009; 6:e1000100.
55. Phillips B, Ball C and Sackett D. Oxford Centre for Evidence-based Medicine-levels of evidence [Updated 2009]. Centre for Evidence-Based Medicine. Website: http://www.cebm.net/index.aspx?o=1025. Accessed September 27, 2015.
56. Wells G, Shea B and O'Connell D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta analyses. Ottawa Hospital Research Institute. Website: http://www.ohri.ca/programs/clinical_ epidemiology/oxford.asp. Accessed September 27, 2015.
57. Hayden JA, Cote P and Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Annals of internal medicine. 2006; 144:427-437.